Skip to main content

Table 3 Associations between immunostaining for E-cadherin and tumour class, stage, grade and histological subtype of RCC.

From: Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma

 

Membranous E-cadherin

Nuclear E-cadherin

 

positive

negative

positive

negative

Tumour class (T)

    

1 (n = 72)

7 (10%)

65 (90%)

34 (47%)

38 (53%)

2 (n = 11)

1 (9%)

10 (91%)

5 (45%)

6 (55%)

3 (n = 59)

5 (8%)

54 (92%)

17 (29%)

42 (71%)

4 (n = 6)

1 (17%)

5 (83%)

3 (50%)

3 (50%)

Stage

    

I (n = 67)

6 (9%)

61 (91%)

32 (48%)

35 (52%)

II (n = 11)

1 (9%)

10 (91%)

5 (45%)

6 (55%)

III (n = 51)

5 (10%)

46 (90%)

13 (25%)

38 (75%)

IV (n = 19)

2 (10%)

17 (90%)

9 (47%)

10 (53%)

Grade

    

I (n = 5)

0 (0%)

5 (100%)

1 (20%)

4 (80%)

II (n = 81)

4 (5%)

77 (95%)

38 (47%)

43 (53%)

III (n = 38)

5 (13%)

33 (87%)

14 (37%)

24 (63%)

IV (n = 22)

3 (14%)

19 (86%)

6 (27%)

16 (73%)

Histological subtype of RCC

    

clear cell (n = 131)

8 (6%)

123 (94%)

52 (40%)

79 (60%)

papillary (n = 10)

0 (0%)

10 (100%)

6 (60%)

4 (40%)

chromophobic (n = 5)

4 (80%)

1 (20%)

1 (20%)

4 (80%)

undifferentiated (n = 2)

2 (100%)

0 (0%)

0 (0%)

2 (100%)

  1. Number of patients with different characteristics and respective membranous and nuclear E-cadherin immunostaining are presented.